Full Year 2022 DiaSorin SpA Earnings Call Transcript
Good morning. This is the Chorus Call conference operator. Welcome, and thank you for joining the DiaSorin Full Year 2022 Results Conference Call. (Operator Instructions) At this time, I would like to turn the conference over to Mr. Carlo Rosa, CEO of DiaSorin. Please go ahead, sir.
Yes. Thank you, operator. Ladies and gentlemen, good afternoon. Welcome to the year-end 2022 results call. As usual, I'm going to make some remarks about the business and then I will leave the microphone to the CFO to go through the actual numbers and guidance for next year.
So let's start to discuss 2022. As usual, I'm making comments at constant exchange rate to understand how the business did progress in the last year. As you know, we have -- we're now used to represent the business, looking at 3 different legs of the company, the Immuno franchise, which is roughly EUR 700 million business, the Molecular business and the LTG business.
The Immuno franchise last year grew 3% with different results
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
